News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Micromedical Implantes to Distribute Misonix Incorporated (MSON)'s SonicOne(R) in Brazil


6/6/2012 10:02:26 AM

FARMINGDALE, N.Y., June 5, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has entered into a new, three year, exclusive distribution agreement with Micromedical Implantes DO Brasil Ltda., based in Sao Paulo, Brazil, for the distribution of the SonicOne® Ultrasonic Wound Cleansing and Debridement System. The agreement provides Micromedical Implantes with the right to sell throughout Brazil. Included in the agreement are annual minimum purchase requirements. Open market sales will commence following the completion of product registration with the government.

Micromedical Implantes has developed special expertise in wound care and has been responsible for introducing several state-of-the-art products into the Brazilian market. They are committed to clinical education and a high level of product support; both attributes are consistent with Misonix's core values.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"We are committed to expanding our wound care franchise in Latin America and the addition of Micromedical Implantes to our distribution organization is important. Brazil is a large and rapidly growing market. We believe there are great opportunities in Brazil for Misonix to become established as a leading surgical instruments provider. This collaboration with Micromedical Implantes represents an important first step in realizing an important strategic objective. Their reputation for successfully introducing new technologies in Brazil is impressive," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.


Investor Relations Contacts

Misonix Contact:

Lytham Partners, LLC

Richard Zaremba

Robert Blum, Joe Dorame, Joe Diaz

631-694-9555

602-889-9700

invest@misonix.com

mson@lythampartners.com

SOURCE Misonix, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES